Cytotoxic activities of 6-arylamino-7-halo-5,8-quinolinediones against human tumor cell lines

  • Chung-Kyu Ryu
  • Hye-Young Kang
  • Yu-Jin Yi
  • Chong-Ock Lee
Research Articles Medicinal Chemistry & Natural Products


6-Arylamino-7-halo-5,8-quinolinediones (4a-4k, 5a-5b) were tested forin vitro cytotoxicity against human solid tumor cell lines such as A 549 (non-small cell lung), SK-OV-3 (ovarian), SK-MEL-2 (melanoma), HCT-15 (colon) and XF 498 (CNS) by SRB assay. The arylamino-7-chloro-5,8-quinolinediones4 were also evaluated for cyclin-dependent kinase (CDK2 and CDK4) inhibitory effect. Among them, the 5,8-quinolinediones4a and5a with 7-(4-fluorophenyl)amino group were found to be potent cytotoxic against HCT 15, SKOV-3 and XF 498, and the compounds4f and4i showed inhibitory activities for the CDK4.

Key words

6-Arylamino-7-halo-5,8-quinolinediones Cytotoxicity Human tumor cell lines CDK4 


  1. Boger, D. L., Yasuda, M., Mitscher, L. A., Drake, S. D., Kitos, P. A. and Thomson, S. C., Streptonigrin and lavandamycin partial structure. A probe for the minimum potent pharmacophore of streptonigrin, lavandamycin and synthetic quinoline-5,8-diones.J. Med. Chem., 30, 1918–1928 (1987).PubMedCrossRefGoogle Scholar
  2. Collins, K., Jacks, T. and Pavletich, N. P., The cell cycle and cancer.Proc. Natl. Acad. Sci. USA, 94 2776–2778 (1997).PubMedCrossRefGoogle Scholar
  3. Dunphy, W. G.,Methods in Enzymology; Cell Cycle Control. Academic Press, San Diego, pp 1–205, 1997; Phelps, D. E. and Xiong, Y. Assay for activity of mammalian cyclin D-dependent kinases CDK4 and CDK6, 194–205; Meijer, L. and Kim, S-.H. Chemical inhibitors of cyclin-dependent kinases, 113–128.Google Scholar
  4. Jeschke, P., Linder, W., Mueller, N. Harder, A. and Mencke, N., New 6(7)amino-substituted-5,8-quinolinediones to combat endoparasites.Eur. Patent., Appl. EP 519, 290 (Cl. C07D215/38) (1992).Google Scholar
  5. Lown, J. W. and Sim, S. K., Studies related to antitumor antibiotics. Synthesis of streptonigrin analogues and their single strand scission of DNA.Can. J. Chem., 54, 2563–2572 (1976).CrossRefGoogle Scholar
  6. Rao, K. V. and Beach, J. W., Streptonigrin and related compounds 5. Synthesis and evaluation of some isoquinolin analogues.J. Med. Chem., 34, 1871–1879 (1991).PubMedCrossRefGoogle Scholar
  7. Rao, K. V. and Rock, C. P., Streptonigrin and related compounds. 6. Synthesis and activity of some quinoxaline analogues.J. Heterocycl. Chem., 33, 447–458 (1996).CrossRefGoogle Scholar
  8. Ryu, C. K. and Kim, H. J., The synthesis of 6-(N-arylamino)-7-chloro-5,8-quinolinedione derivatives for evaluation of antifungal activities.Arch. Pharm. Res., 17, 139–144 (1994).CrossRefGoogle Scholar
  9. Ryu, C. K., Lee, I. K., Jung, S. H. and Lee, C. O., Synthesis and cytotoxic activities 6-chloro-7-arylamino-5,8-isoquinolinediones.Bioorg. Med. Chem. Lett., 9(8), 1075–1080 (1999a).PubMedCrossRefGoogle Scholar
  10. Ryu, C. K., Jung, S. H., Lee, J. A., Kim, H. J., Lee, S. H. and Chung, J. H., 6-Arylamino-5,8-quinolinediones and 7-arylamino-5,8-isoquinolinediones as inhibitors of endothelium-dependent vasorelaxation.Bioorg. Med. Chem. Lett., 9(17), 2466–2472 (1999b).CrossRefGoogle Scholar
  11. Sausville, E. A., Zahararevitz, D., Gussio, R., Meijer, L., Louarn-Leost, M., Kunick, C., Schultz, R., Lahusen, T., Headlee, D., Stinson, S., Arbuck, S. G. and Senderowicz, A., Cyclin-dependent kinases: Initial approaches to exploit a novel therapeutic target.Pharmacol. Ther., 82 285–292 (1999).PubMedCrossRefGoogle Scholar
  12. Schellhammer, C. W. and Petersen, S., Ueber Derivatives des 5,8-Chinolinchinone.Ann. der Chem., 624, 108–119 (1959).Google Scholar
  13. Shaikh, I. A., Johnson, F. and Grollman, A. P., Structure-activity relationship among simple bicyclic analogues. Rate dependent of DNA degradation on quinone reduction potential.J. Med. Chem., 29, 1329–1340 (1986).PubMedCrossRefGoogle Scholar
  14. Skehan, P., Storeng, R., Scudiero, D., Monks, A., McMahon, J., Vistica, D., Warren, T. W., Bokesch, H., Kenney, S. and Boyd, M. R., New colorimetric cytotoxicity assay for anticancer-drug screening.J. Natl. Cancer Inst., 82, 1107–1112 (1990).PubMedCrossRefGoogle Scholar
  15. Webster, K. R., The therapeutic potential of targeting the cell cycle.Exp. Opin. Invest. Drugs, 7(6), 865–887, (1998).CrossRefGoogle Scholar
  16. Yasuda, M. and Boger, D. L., Streptonigrin and lavandamycin partial structure. A probe for the minimum potent pharmacophore of the natural occurring antitumor-anitibiotics.J. Heterocycl. Chem., 24, 1253–1259 (1987).Google Scholar

Copyright information

© The Pharmaceutical Society of Korea 1999

Authors and Affiliations

  • Chung-Kyu Ryu
    • 1
  • Hye-Young Kang
    • 1
  • Yu-Jin Yi
    • 1
  • Chong-Ock Lee
    • 2
  1. 1.College of PharmacyEwha Womans UniversitySeoulKorea
  2. 2.Korea Research Institute of Chemical TechnologyTaejonKorea

Personalised recommendations